IPSC Century Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: IPSC
Price (delayed)
$0.539
Market cap
$46.56M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.29
Enterprise value
$33.57M
Relative Growth:
Rel. Growth:
37
Relative Strength:
Rel. Strength:
19
Relative Valuation:
Rel. Valuation:
36
Relative Profitability:
Rel. Profitability:
51
Highlights
The EPS has surged by 86% year-on-year
The debt has declined by 12% year-on-year and by 2.5% since the previous quarter
Century Therapeutics's net income has soared by 82% YoY but it has decreased by 6% from the previous quarter
The quick ratio has declined by 8% since the previous quarter but it has increased by 2% year-on-year
The equity has declined by 13% since the previous quarter and by 5% year-on-year
Key stats
What are the main financial stats of IPSC
Market
Valuations
Earnings
Shares outstanding
86.39M
Market cap
$46.56M
Enterprise value
$33.57M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.22
Price to sales (P/S)
0.41
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.29
Revenue
$114.13M
Gross profit
$114.13M
Operating income
-$32.56M
Net income
-$23.28M
EBIT
-$21.51M
EBITDA
-$7.37M
Free cash flow
-$114.91M
Per share
Balance sheet
Liquidity
EPS
-$0.29
EPS diluted
-$0.29
Free cash flow per share
-$1.33
Book value per share
$2.44
Revenue per share
$1.32
TBVPS
$2.9
Total assets
$284.69M
Total liabilities
$74.79M
Debt
$46.59M
Equity
$209.9M
Working capital
$145.22M
Debt to equity
0.22
Current ratio
10.72
Quick ratio
10.61
Net debt/EBITDA
1.76
Margins
Efficiency
Dividend
EBITDA margin
-6.5%
Gross margin
100%
Net margin
-20.4%
Operating margin
-28.5%
Return on assets
-6.9%
Return on equity
-11.5%
Return on invested capital
-8.7%
Return on capital employed
-8%
Return on sales
-18.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IPSC stock price
How has the Century Therapeutics stock price performed over time
Intraday
-3.72%
1 week
-8.95%
1 month
-2.94%
1 year
-61.22%
YTD
-46.63%
QTD
8.23%
Financial performance
How have Century Therapeutics's revenue and profit performed over time
Revenue
$114.13M
Gross profit
$114.13M
Operating income
-$32.56M
Net income
-$23.28M
Gross margin
100%
Net margin
-20.4%
Century Therapeutics's operating margin has surged by 100% YoY
The net margin has surged by 100% year-on-year but it has declined by 7% since the previous quarter
Century Therapeutics's net income has soared by 82% YoY but it has decreased by 6% from the previous quarter
The company's operating income has surged by 78% YoY
Price vs fundamentals
How does IPSC's price correlate with its fundamentals
Growth
What is Century Therapeutics's growth rate over time
Valuation
What is Century Therapeutics stock price valuation
P/E
N/A
P/B
0.22
P/S
0.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.29
The EPS has surged by 86% year-on-year
IPSC's price to book (P/B) is 82% lower than its 5-year quarterly average of 1.3 and 43% lower than its last 4 quarters average of 0.4
The equity has declined by 13% since the previous quarter and by 5% year-on-year
The price to sales (P/S) is 97% lower than the last 4 quarters average of 16.7
Efficiency
How efficient is Century Therapeutics business performance
The return on sales has surged by 100% year-on-year but it has declined by 7% since the previous quarter
Century Therapeutics's ROE has soared by 82% YoY but it has decreased by 7% from the previous quarter
Century Therapeutics's return on assets has surged by 80% YoY but it has decreased by 15% QoQ
The ROIC has soared by 77% YoY but it has contracted by 23% from the previous quarter
Dividends
What is IPSC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IPSC.
Financial health
How did Century Therapeutics financials performed over time
Century Therapeutics's total liabilities has shrunk by 62% YoY
Century Therapeutics's total assets has decreased by 32% YoY and by 10% QoQ
The debt is 78% smaller than the equity
The equity has declined by 13% since the previous quarter and by 5% year-on-year
The debt has declined by 12% year-on-year and by 2.5% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.